Federal Register / Vol. 72, No. 122 / Tuesday, June 26, 2007 / Notices 35057 

ovarian carcinomas, and has the 

potential of being used as a tumor 

marker and a novel target for the 

development of new treatments. 

The technology relates to the finding 

that some non-small cell lung cancers 

(NSCLC) express the antigen 

mesothelin. Targeting the tumors with 

antibodies or immunotoxins that 

specifically bind mesothelin can be a 

potential new treatment for non-small 

cell lung cancer. The SSIP immunotoxin 

and its variants that specifically bind to 

mesothelin can be used for the 

treatment of NSCLC. 

Applications and Modality: NSCLC 

can be treated by targeting mesothelin. 

Advantage: Anti-mesothelin 

antibodies and immunotoxins are 

already available and being tested for 

several cancers. 

Development Status: The technology 

is in pre-clinical stage of development. 

Inventors: Ira H. Pastan (NCI) et al. 

Patent Status: U.S. Provisional 

Application No. 60/891,923 filed 27 Feb 

2007 (HHS Reference No. E–120–2007/ 

0–US–01), entitled ‘‘Treatment of NonSmall Cell Lung Cancer with 

Mesothelin-Targeted Immunotoxins.’’

Licensing Status: Available for 

exclusive and non-exclusive licensing. 

Licensing Contact: Jesse S. Kindra, 

J.D.; 301–435–5559; 

kindraj@mail.nih.gov 

Collaborative Research Opportunity: 

The National Cancer Institute’s 

Laboratory of Molecular Biology is 

seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate, or commercialize 

anti-mesothelin antibodies and 

immunotoxins. Please contact John D. 

Hewes, Ph.D. at 301–435–3121 or 

hewesj@mail.nih.gov for more 

information. 

A Gene Expression Profile That 

Predicts Ovarian Cancer Patient 

Response to Chemotherapy 

Description of Technology: Ovarian 

cancer is a poor prognosis disease that 

remains the most lethal of all 

gynecologic malignancies. Warning 

symptoms do not occur until the tumor 

has already spread beyond the ovary, 

resulting in diagnosis at an advanced 

stage. As a result, there is a poor patient 

prognosis with only fifteen percent of 

women possessing advanced stage 

disease surviving for five years. Despite 

an initial clinical response of 80% to 

surgery and chemotherapy, most 

patients experience tumor recurrence 

within two years of treatment. The 

overwhelming majority of these patients 

will eventually develop chemoresistant 

disease and die. 

Available for licensing are two gene 

signatures. One gene signature can 

predict whether a patient will initially 

respond to standard platinum-paclitaxel 

chemotherapy, but will relapse within 

six months of completing treatment. A 

second gene signature identifies patients 

who will show no response to therapy. 

This methodology may enable clinicians 

to identify patients who may be 

candidates for additional and/or novel 

chemotherapy drugs, and effectively 

choose appropriate cancer treatment. A 

unique feature of this signature is its 

derivation from pure, microdissected 

isolates of ovarian tumor cells, rather 

than undissected tissue. By utilizing 

this approach, the resulting gene list is 

specific to the cell type that causes the 

disease. 

Applications: Method to detect if an 

ovarian cancer patient is sensitive to 

treatment with chemotherapeutic 

agents; Method to evaluate ovarian 

cancer patient chemoresponsiveness; 

Diagnostic tool to aid clinicians in 

determining appropriate cancer 

treatment; Methods to treat ovarian 

cancer identified by chemoresistant 

biomarkers compositions. 

Market: Ovarian cancer is the fourth 

most common form of cancer in the 

U.S.; Ovarian cancer is three times more 

lethal than breast cancer; 15,310 deaths 

in the U.S. in 2006. 

Development Status: The technology 

is currently in the pre-clinical stage of 

development. 

Inventors: Michael J. Birrer (NCI) et al. 

Publication: SC Mok et al. Biomarker 

discovery in epithelial ovarian cancer 

by genomic approaches. Adv Cancer 

Res. 2007;96:1–22. 

Patent Status: U.S. Provisional 

Application No. 60/899,942 filed 06 

Feb. 2007 (HHS Reference No. E–060–

2007/0–US–01). 

Licensing Status: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: Jennifer Wong; 

301/435–4633; wongje@mail.nih.gov. 

Potent, Easy to Use Targeted Toxins as 

Anti-Tumor Agents 

Description of Technology: The 

invention discloses synthesis and use of 

novel derivatives of 2-[2′-(2- 

aminoethyl)-2-methyl-ethyl]-1,2- 

dihydro-6-methoxy-3H-dibenz- 

[de,h]isoquinoline-1,3-dione as targeted 

anti-tumor agents. The use of targeted 

toxin conjugates with anti-cancer 

antibodies, such as herceptin, is 

increasing. Based on a comparison with 

the structurally complex toxins, such as 

DM1, available in the market, these 

novel toxins are more stable in 

circulation, thus making the toxinconjugates more tumor-selective and 

less toxic. As such, these compounds 

are superior alternatives to the existing 

toxins. 

The invention describes a potent and 

easy to synthesize toxin that can be used 

for generating a variety of prodrugs. 

These compounds can be attached to a 

ligand that recognizes a receptor on 

cancer cells, or to a peptide that is 

cleaved by tumor-specific proteases. 

The compounds are topoisomerase 

inhibitors and are mechanistically 

different from DM1 that targets tubulin. 

The structure of the toxin allows it to 

be modified with a peptide linker that 

is stable, but rapidly cleaved in 

lysosomes after the compound is 

specifically taken up by cancer cells. 

Applications: The compounds can be 

used for preparation of a variety of 

potent anti-cancer agents with low 

systemic toxicity. 

Advantages: Easy to prepare; 

Structural features make these 

compounds more stable in circulation; 

Toxin conjugates are more tumorselective and less toxic. 

Benefits: 600,000 cancer deaths 

occurred in 2006 in spite of advances in 

cancer therapeutics. A major limitation 

of current therapeutics is their toxic side 

effects. This technology can effectively 

treat cancer with low systemic toxicity 

and thus improve overall survival and 

quality of life of patients suffering from 

cancer. The current cancer 

chemotherapeutic market is valued at 

$42 billion and expected to grow. 

Inventors: Nadya I. Tarasova, Marcin 

D. Dyba, Christopher J. Michejda (NCI). 

Development Status: In vitro studies 

are completed and in vivo animal model 

studies are ongoing. 

Patent Status: U.S. Provisional 

Application No. 60/844,027 filed 12 

Sep. 2006 (HHS Reference No. E–160–

2006/0–US–01). 

Licensing Contact: Mojdeh Bahar, J.D.; 

301/435–2950; baharm@mail.nih.gov. 

Dated: June 19, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–12337 Filed 6–25–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Amended Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the National Heart, Lung, 

and Blood Institute Special Emphasis 


jlentini on PROD1PC65 with NOTICES
35058 Federal Register / Vol. 72, No. 122 / Tuesday, June 26, 2007 / Notices 

Panel, July 18, 2007, 8 a.m. to July 18, 

2007, 6 p.m., Hilton Crystal City, 2399 

Jefferson Davis Hwy., Arlington, VA 

22202 which was published in the 

Federal Register on June 15, 2007, FR 

07–2972. 

The meeting location was changed 

from Hilton Crystal City to State Plaza 

Hotel, Washington, DC. The rest of the 

information remains the same. The 

meeting is closed to the public. 

Dated: June 20, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–3118 Filed 6–25–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel, 

Institutional National Research Service 

Award (T32s). 

Date: July 10, 2007. 

Time: 2 p.m. to adjournment. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Roy L. White, PhD, Review 

Branch/DERA, National Heart, Lung, and 

Blood Institute, 6701 Rockledge Drive, Room 

7176, Bethesda, MD 20892-7924, 301–435–

0310, whiterl@nhlbi.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: June 20, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–3121 Filed 6–25–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institute on Alcohol Abuse 

and Alcoholism; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Alcohol Abuse and Alcoholism Special 

Emphasis Panel, Fellowships SEP HH–92. 

Date: July 31, 2007. 

Time: 8:30 a.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Doubletree, Bethesda, MD. 

Contact Person: Lorraine Gunzerath, PhD, 

MBA, Scientific Review Administrator, 

National Institute on Alcohol Abuse and 

Alcoholism, Office of Extramural Activities, 

Extramural Project Review Branch, 5635 

Fishers Lane, Room 3043, Bethesda, MD 

20892–9304, 301–443–2369, 

lgunzera@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.271, Alcohol Research 

Career Development Awards for Scientists 

and Clinicians; 93.272, Alcohol National 

Research Service Awards for Research 

Training; 93.273, Alcohol Research Programs; 

93.891, Alcohol Research Center Grants, 

National Institutes of Health, HHS) 

Dated: June 19, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–3122 Filed 6–25–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of General Medical 

Sciences; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Minority Programs 

Review Committee, MBRS Review 

Subcommittee B. 

Date: July 16–17, 2007. 

Time: 8:30 a.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Rebecca H. Johnson, PhD, 

Office of Scientific Review, National Institute 

of General Medical Sciences, National 

Institutes of Health, Natcher Building, Room 

3AN18C, Bethesda, MD 20892, 301–594–

2771, Johnsonrh@nigms.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.375, Minority Biomedical 

Research Support; 93.821, Cell Biology and 

Biophysics Research; 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.862, Genetics and 

Developmental Biology Research; 93.88, 

Minority Access to Research Careers; 93.96, 

Special Minority Initiatives, National 

Institutes of Health, HHS) 

Dated: June 19, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–3123 Filed 6–25–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Alcohol Abuse 

and Alcoholism; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Commission Act, as 

amended (5 U.S.C. Appendix 2), notice 


jlentini on PROD1PC65 with NOTICES